Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test® to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test® to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.
Learn More

Introducing the Syn-One Test® from CND Life Sciences

Offering physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy.

seal icon

CLIA-Certified Pathology Lab

test tube icon

Dedication to Science & Research

DNA icon

Patient-Focused Mission

microscope icon

Quality & Reliability at Our Core

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
May 31, 2023

Incorporating Skin Biopsy Testing for Alpha-Synuclein Into Your Practice

Across an array of neurologic diseases, there is often a lack of objective diagnostic testing.…
Insights
April 20, 2023

Dr. Christopher Gibbons Interviewed on Neurology Podcast About Alpha-Synuclein Signatures Study

Dr. Christopher Gibbons was interviewed by Dr. Jason Crowell last week on the Neurology® podcast…
Insights
March 20, 2023

Using Cutaneous Synuclein Biosignatures to Distinguish Parkinson’s Disease From Multiple System Atrophy

A recent paper published in Neurology and co-authored by two of CND Life Sciences’ co-founders,…
VIEW ALL INSIGHTS

Check out press releases, news alerts and coverage of CND happenings.

CND In the News
May 18, 2023

A Roundup of Syn-One Study Results Coverage from AAN 2023

Topline results from the Synuclein-One Study, presented at the American Academy of Neurology Annual Meeting…
On Our Radar
May 11, 2023

Study Examines Diagnostic Utility of Syn-One Test® vs DaTscan

In a poster presented at the American Academy of Neurology 2023 Annual Meeting, researchers from…
On Our Radar
May 4, 2023

Skin Biopsy Using Immunofluorescence More Accurate Than Seed Amplification Assay in Detecting Alpha-Synuclein in RBD Patients

A study published this week in NJP Parkinson’s Disease compared two methods of detecting alpha-synuclein…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our free Skin Biopsy Test Kit, simply collect three small skin biopsies from your patient, send them to our CLIA-certified lab, and CND will provide important visual insights to support a diagnosis.

Order a Kit